Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Emiko Kurosawa"'
Autor:
Aiko Ishiki, Emiko Kurosawa, Daiki Narai, Yuta Sakai, Youtaro Arima, Akinobu Aihara, Toshihiro Yamagata, Yoshihisa Katsuta, Shigeto Mashiko, Tomoya Oizumi, Katsutoshi Furukawa
Publikováno v:
Frontiers in Medicine, Vol 11 (2024)
Externí odkaz:
https://doaj.org/article/70af736382114390afb088d13db58404
Autor:
Takuya Yamaguchi, Akinobu Aihara, Shigeto Mashiko, Emiko Kurosawa, Tomoya Oizumi, Toshihiro Yamagata, Aiko Ishiki, Juri Ueda, Yuko Fujikawa, Atsuhiro Kanno, Kazuhiro Sumitomo, Takahiro Ohara, Katsutoshi Furukawa
Publikováno v:
Frontiers in Medicine, Vol 11 (2024)
IntroductionParkinson’s disease (PD) is a disorder characterized by motor symptoms, such as rigidity, akinesia, and resting tremor, as well as non-motor symptoms, including psychiatric manifestations and autonomic failure. The prevalence of PD incr
Externí odkaz:
https://doaj.org/article/aa0d8364cba9402b82b88d7c796af1a9
Autor:
Atsuhiro Kanno, Kazuhiro Sumitomo, Daiki Narai, Kohei Suzuki, Yoshihisa Katsuta, Emiko Kurosawa, Tomoya Oizumi, Shigeto Mashiko, Takahiro Ohara, Katsutoshi Furukawa
Publikováno v:
Geriatrics & Gerontology International.
Autor:
Akiko Tanaka, Yutaka Nakamura, Isao Ohno, Musashi Abe, Naruo Yoshimura, Emiko Kurosawa, Azusa Otomo, Takashi Ohrui
Publikováno v:
Respiratory Disease Series: Diagnostic Tools and Disease Managements ISBN: 9789811545054
Aspiration is defined as the entry of oropharyngeal or gastric contents into the larynx and the lower respiratory tract. Aspiration is often the result of impaired swallowing, which allows oropharyngeal or gastric contents to enter the lungs, especia
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1f7bcb064a67e15e5402fd88bea56263
https://doi.org/10.1007/978-981-15-4506-1_3
https://doi.org/10.1007/978-981-15-4506-1_3
Autor:
Naruo Yoshimura, Akiko Tanaka, Masahito Ebina, Hidenori Takahashi, Takashi Ohrui, Emiko Kurosawa
Publikováno v:
Annals of Oncology. 30:vi139
Osimertinib is a third-generation tyrosine kinase inhibitor (TKI) of the epidermal growth factor receptor (EGFR) that has been approved for the treatment of metastatic non-small cell lung cancer (NSCLC) with EGFR mutation, and positive for the second